Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are the second most common group of drugs leading to the development of drug-induced liver injury (DILI). Objective: to determine the clinical features of DILI in patients with gout when using NSAIDs. Material and methods. The study is monocentric, observational, retrospective. Performed in the period from 2012-01-01 to 2020-12-31 in the Rheumatology Department of the 11th City Clinical Hospital. The study included 527 patients with gouty arthritis (GA). The type of DILI was determined in accordance with the recommendations of EASL, 2019. An updated scale RUCAM (Roussel Uclaf Causality Assessment Method) was used to assess causal relationships. Results. DILI was detected in 91 patients (14.3%), in 80 – hepatocellular, in 11 - mixed type of DILI. The 1st category of DILI severity was stated in 88, the 2nd category – in 3 patients. We observed DILI more often in younger patients without severe comorbidity, but with an alcoholic surplus preceding a GA attack and, after, during attack an excess of the average therapeutic doses of NSAIDs was registered. Conclusions. Thus, we did not observe a severe course of DILI in patients taking NSAIDs for the relief of GA. However, NSAID hepatotoxicity in this category of patients is a social and medical problem.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
